ArticleBMC cardiovascular disorders2026
The CML/esRAGE ratio as a potential biomarker of early diastolic impairment in asymptomatic type 1 diabetic patients without overt heart disease.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure is a prevalent complication of diabetic microangiopathy, and early identification of myocardial dysfuntion is crucial. Advanced glycation end products (AGEs) bind to their receptor RAGE and further promote diabetic late complications as well as heart failure. Two soluble RAGE isoforms, endogenous secretory RAGE (esRAGE) and the cleaved extracellular fragment of membrane RAGE (collectively termed sRAGE), are believed to exert cardioprotective effects by acting as RAGE decoy receptors. This pilot study aimed to investigate the associations of AGEs, sRAGE and esRAGE with early cardiac dysfunction identified via advanced echocardiography.
methodsWe enrolled 29 type 1 diabetic patients without known heart disease(EF ≥ 50%) and 31 healthy controls. Plasma levels of two major AGEs, carboxymethyllysine(CML) and methylglyoxal-derived hydroimidazolone 1(MG-H1), as well as sRAGE and esRAGE were measured using immunoassay. Conventional, tissue Doppler, and speckle-tracking echocardiography were performed.
resultsIn the diabetic group, global longitudinal strain (GLS) and peak early diastolic velocity at the lateral mitral annulus [e(lat)] were significantly lower, while E/e(lat) was higher. CML levels and CML/esRAGE ratio were increased, and esRAGE was decreased in the diabetic group. Pearson correlation analysis showed GLS was significantly associated with disease duration, total cholesterol (TC), HbA1c, esRAGE, and CML/esRAGE ratio; Univariate linear regression confirmed that higher CML/esRAGE ratio was associated with lower e(lat) (β = -0.006, P = 0.047).Variables with P < 0.1 in univariate regression together with pre-specified clinical covariates including age, gender, HbA1c, disease duration, and heart rate were incorporated into stepwise multiple regression; the model demonstrated that CML/esRAGE was independently associated with e(lat) (β = -0.006, 95%CI: [-0.012, -0.001], P = 0.049).
conclusionElevated CML/esRAGE ratio is associated with impaired left ventricular diastolic function, and may represent a candidate biomarker for early diastolic dysfunction. Our study also suggest that CML/esRAGE ratio may not associated with GLS abnormalities reflecting subclinical systolic dysfunction. All observations from this pilot study require further validation in large independent prospective cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.